Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.48 |
| ▸ | PPARA | Q07869 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447232 | 0.87 | PPARG (0.45) | PPARGPPARAALDH1A1LMNA | |
| SCHEMBL29770828 | 0.78 | ALDH1A1 (0.61) | PPARGPPARAALDH1A1GAAMAPT | |
| SCHEMBL1931922 | 0.78 | ALDH1A1 (0.61) | PPARGPPARAALDH1A1GAAMAPT | |
| SCHEMBL5312651 | 0.77 | PPARG (0.61) | PPARGPPARAALDH1A1GAAMAPT | |
| SCHEMBL7646415 | 0.74 | HSD11B1 (0.54) | TSHRLMNAMEN1KMT2A | |
| SCHEMBL14596729 | 0.74 | RAB9A (0.68) | ALDH1A1GAAMAPTLTB4R2LMNA | |
| SCHEMBL9045444 | 0.74 | ALDH1A1 (0.54) | PPARGPPARAALDH1A1GAAMAPT | |
| SCHEMBL25685762 | 0.74 | ALDH1A1 (0.54) | PPARGPPARAALDH1A1GAAMAPT | |
| SCHEMBL4630402 | 0.73 | PPARG (0.49) | PPARGPPARAALDH1A1LTB4R2MEN1 | |
| SCHEMBL8365095 | 0.72 | PPARG (0.52) | PPARGPPARAALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| EP-1622869-A1 | GLYOXALASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101506-A1 | GLYOXALASE INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | GLO1, LOX, LOXL1 | PPARG 4267/4885PPARA 4574/4885ALDH1A1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.